BR100 Increased By (0.29%)
BR30 Increased By (0.37%)
KSE100 Increased By (0.07%)
KSE30 Increased By (0.23%)
AGHA 7.75 Decreased By ▼ -0.17 (-2.15%)
BECO 5.20 No Change ▼ 0.00 (0%)
BML 58.30 Decreased By ▼ -0.95 (-1.6%)
BOP 33.95 Increased By ▲ 0.27 (0.8%)
CNERGY 10.63 Increased By ▲ 0.82 (8.36%)
CSIL 5.30 Decreased By ▼ -0.12 (-2.21%)
FCCL 53.75 Increased By ▲ 0.23 (0.43%)
FFL 16.50 Decreased By ▼ -0.18 (-1.08%)
FNEL 1.24 Increased By ▲ 0.03 (2.48%)
KEL 7.30 Decreased By ▼ -0.05 (-0.68%)
KOSM 5.61 No Change ▼ 0.00 (0%)
LOTCHEM 29.87 Increased By ▲ 0.76 (2.61%)
MLCF 96.30 Increased By ▲ 0.80 (0.84%)
NBP 204.40 Increased By ▲ 0.05 (0.02%)
NCPL 57.06 Decreased By ▼ -1.18 (-2.03%)
NPL 67.45 Decreased By ▼ -0.34 (-0.5%)
OGDC 317.99 Increased By ▲ 0.05 (0.02%)
PACE 10.64 Decreased By ▼ -0.07 (-0.65%)
PAEL 41.90 Increased By ▲ 0.07 (0.17%)
PIBTL 16.78 Increased By ▲ 0.28 (1.7%)
PPL 220.44 Increased By ▲ 0.70 (0.32%)
PRL 49.05 Increased By ▲ 4.46 (10%)
PTC 69.80 Decreased By ▼ -0.97 (-1.37%)
SSGC 29.26 Increased By ▲ 0.33 (1.14%)
TBL 9.78 Decreased By ▼ -0.06 (-0.61%)
TELE 8.89 Increased By ▲ 0.13 (1.48%)
TPL 17.08 Increased By ▲ 0.63 (3.83%)
TPLP 12.56 Increased By ▲ 0.46 (3.8%)
TREET 22.72 Decreased By ▼ -0.08 (-0.35%)
TRG 60.26 Increased By ▲ 0.23 (0.38%)
World

US CDC recommends boosters targeting Omicron

Published Updated
By

WASHINGTON: The US Centers for Disease Control and Prevention (CDC) on Thursday recommended Covid-19 booster shots from Pfizer and Moderna targeting the Omicron variant, clearing the way for the administration of the shots.

This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States.

The Pfizer-BioNTech shot is recommended for people 12 and older and Moderna’s for those 18 years and up.

“The updated Covid-19 boosters are formulated to better protect against the most recently circulating Covid-19 variant. They can help restore protection that has waned since previous vaccination and were designed to provide broader protection against newer variants,” CDC Director Rochelle Walensky said in a statement.

“This recommendation followed a comprehensive scientific evaluation and robust scientific discussion,” she added.

COVID drives down US life expectancy for the second straight year

The new versions of the vaccines – which were approved by the US Food and Drug Administration on Wednesday – could potentially be available in the United States as early as next week.

The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.

In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.

Comments

Comments are closed for this article.